When Aurinia Pharmaceuticals launched their first FDA-approved product, LUPKNIS© (voclosporin), they recognised the need for a modern, scalable PV infrastructure.
Reportum© was deployed which has enabled Aurinia to capture high-quality adverse event and product quality data directly from patients, healthcare professionals and programs like specialty pharmacies.
